B. Riley Expects Lower Earnings for Centessa Pharmaceuticals
Equities research analysts at B. Riley lowered their Q1 2025 earnings estimates for shares of Centessa Pharmaceuticals in a ...
B. Riley Financial: Surprise Debt Exchange Is Positive, But Major Challenges Remain
B. Riley Financial, Inc. tackles its $723M debt wall through a strategic transaction. Click here to find out why RILY stock ...
Wall Street Predicts More Growth For Digital Banking Platform Dave: Here's What You Need To Know
Digital banking platform, Dave (NASDAQ: DAVE) has been on a fiery streak in recent months, up 121% since November 2024.
FY2027 EPS Estimates for Journey Medical Cut by B. Riley
Equities research analysts at B. Riley decreased their FY2027 earnings per share (EPS) estimates for Journey Medical in a ...
Why B. Riley Financial (RILY) Stock Is Trading Higher
B. Riley Financial shares are trading higher by 9.6% during Wednesday's session. The company entered an exchange agreement to ...
Vaxart price target lowered to $2 from $2.50 at B. Riley
B. Riley analyst Mayank Mamtani lowered the firm’s price target on Vaxart (VXRT) to $2 from $2.50 and keeps a Buy rating on the shares. The Q4 ...
BRT Apartments price target lowered to $21 from $22 at B. Riley
B. Riley lowered the firm’s price target on BRT Apartments (BRT) to $21 from $22 and keeps a Buy rating on the shares. The ...
B. Riley Shares Rise After Agreeing to Reduce Debt
B. Riley has been struggling financially as its share value sank nearly 100% over the past three years. Franchise Group, the holding company for the Vitamin Shoppe--which B. Riley was heavily invested ...